Fundraising Fox
/Companies
Sign in

Superluminal Medicines

Waltham, US · Founded 2023 · Delaware corporation · 5 known investors

Find your way into Superluminal Medicines

Sign up to see every warm intro you have to Superluminal Medicines

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Superluminal Medicines team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Uses ML and big data to accelerate drug development.

AI & Machine LearningBiotechDeep TechHealthtechMedical Devices

Founders & leadership

Superluminal Medicines was founded in 2023 by Ajay Yekkirala, PhD and Ryan Bloom.

AYAjay Yekkirala, PhD
Ajay Yekkirala, PhDCo-founder & Chief Scientific OfficerAjay Yekkirala, PhD, founded Superluminal Medicines after more than 17 years working in life science drug discovery and development across industry and academia. He brings experience in biotech business strategy and building partnerships with key opinion leaders, subject matter experts, and investors to advance CNS disease research.
RBRyan Bloom
Ryan BloomCo-founder · SVP, Business Development and OperationsRyan Bloom held corporate development and strategy roles focused on scientific and clinical diligence, deal structuring, and financing across oncology and regenerative medicine, and now leads Superluminal Medicines, which uses machine learning and big data to accelerate drug development.
CR
CATHERINE RIESENExecutive
CD
CONY D'CRUZExecutive
CR
CRAIG RANDALLNamed on SEC filing
AY
Ajay YekkiralaFounder
AY
Ajay Yekkirala Cony D'CruzFounder
CD
Cony D'CruzFounder

Board

DX
DIAMANTIS XYLASBoard director
DMDYLAN MORRIS
DYLAN MORRISBoard DirectorManaging Director at Insight Partners
ALANDREW LEVIN
ANDREW LEVINBoard directorPartner at RA Capital
NSNANDITA SHANGARI
NANDITA SHANGARIBoard directorManaging Director at RA Capital

Investors · 5

RA Capitallisted by RA CapitalBostonvia Andrew Levin · board

How we know: RA Capital's portfolio page · board seat on SEC Form D · funding news · Not right? Tell us

Insight PartnersreportedNew York · $120M – $350M

How we know: a partner's Signal profile · funding news · press coverage · open dataset · 5k.vc investor directory · Not right? Tell us

NVenturesreportedSanta Clara

How we know: the VCSheet dataset · Not right? Tell us

NVIDIAreportedSanta Clara

How we know: funding news · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$116.2M disclosed across 4 rounds · 2023–2026

▶$65.5MraisedSep 2026 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • CONY D'CRUZExecutive Officer, Director, Promoter
  • NANDITA SHANGARIDirector
  • DYLAN MORRISDirector
  • DIAMANTIS XYLASDirector
  • HARSHA PALADUGUDirector
Offering amount
$65.5M
Amount sold
$65.5M
First sale
Aug 2026
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedAug 2025 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • DYLAN MORRISDirector
  • ANDREW LEVINDirector
  • DIAMANTIS XYLASDirector
  • CONY D'CRUZExecutive Officer, Director, Promoter
Offering amount
$5M
Amount sold
$5M
First sale
Aug 2025
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20MraisedSep 2024 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • DIAMANTIS XYLASDirector
  • DYLAN MORRISDirector
  • CATHERINE RIESENExecutive Officer
  • CONY D'CRUZExecutive Officer, Director, Promoter
  • ANDREW LEVINDirector
Offering amount
$120M
Amount sold
$20M
First sale
Aug 2024
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25.7MraisedAug 2023 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • CATHERINE RIESENExecutive Officer
  • ANDREW LEVINDirector
  • CRAIG RANDALLExecutive Officer
  • CONY D'CRUZExecutive Officer, Director, Promoter
  • DYLAN MORRISDirector
Offering amount
$25.7M
Amount sold
$25.7M
First sale
Mar 2023
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Superluminal Medicines went on to found or lead other companies.

Aiden AcevesBoard ObserverFounded Primmune TherapeuticsAndrew LevinDirectorFounded Climb Bio

Frequently asked questions

What does Superluminal Medicines do?
Uses ML and big data to accelerate drug development.
Who founded Superluminal Medicines?
Superluminal Medicines was founded by Ajay Yekkirala, PhD, Ryan Bloom in 2023.
Who are Superluminal Medicines's investors?
Superluminal Medicines's investors include Gaingels, RA Capital, Insight Partners, NVentures, NVIDIA.
How much funding has Superluminal Medicines raised?
Superluminal Medicines has disclosed $116.2M raised across 4 rounds.
Where is Superluminal Medicines headquartered?
Superluminal Medicines is headquartered in Waltham, US.